Mitoquinone for Postmenopausal Brain Health
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are:
Does MitoQ improve cerebrovascular function in postmenopausal women?
If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries?
Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function.
Participants will:
Take MitoQ (20 mg/day) or a placebo every day for 3 months
Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point
Keep track of symptoms and events during their treatment period to report to the study team
Are You a Good Fit for This Trial?
This trial is for postmenopausal women aged 60 or older who are in good health and not suffering from any clinical diseases. It's designed to see if a dietary supplement can improve the health of brain arteries affected by aging and menopause.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take MitoQ (20 mg/day) or a placebo every day for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MitoQ
Trial Overview
The study tests MitoQ, an antioxidant targeting mitochondria, against a placebo to determine if it improves cerebrovascular function by reducing mitochondrial oxidative stress. Participants will take either MitoQ or placebo daily for three months with evaluations at the start, midpoint, and end.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
Matched placebo capsules.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Colorado State University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.